These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 19392926)
1. New antiplatelet drugs: beyond aspirin and clopidogrel. Siddique A; Butt M; Shantsila E; Lip GY Int J Clin Pract; 2009 May; 63(5):776-89. PubMed ID: 19392926 [TBL] [Abstract][Full Text] [Related]
2. New antiplatelet agents: why they are needed. Franchini M; Mannucci PM Eur J Intern Med; 2009 Dec; 20(8):733-8. PubMed ID: 19892299 [TBL] [Abstract][Full Text] [Related]
3. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242 [TBL] [Abstract][Full Text] [Related]
4. Clinical overview of promising nonthienopyridine antiplatelet agents. Angiolillo DJ; Guzman LA Am Heart J; 2008 Aug; 156(2 Suppl):S23-8. PubMed ID: 18657683 [TBL] [Abstract][Full Text] [Related]
5. Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice? Heras M; del Río A Am J Cardiovasc Drugs; 2009; 9 Suppl 1():13-7. PubMed ID: 20000883 [TBL] [Abstract][Full Text] [Related]
6. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. White HD Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598 [TBL] [Abstract][Full Text] [Related]
7. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome. Packard KA; Campbell JA; Knezevich JT; Davis EM Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457 [TBL] [Abstract][Full Text] [Related]
12. Novel antiplatelet agents in development: prasugrel, ticagrelor, and cangrelor and beyond. Shalito I; Kopyleva O; Serebruany V Am J Ther; 2009; 16(5):451-8. PubMed ID: 19262362 [TBL] [Abstract][Full Text] [Related]
13. Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease. Zeidner JF; Frishman WH; Lerner RG Cardiol Rev; 2008; 16(5):250-9. PubMed ID: 18708826 [TBL] [Abstract][Full Text] [Related]
14. The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Behan MW; Chew DP; Aylward PE Curr Opin Cardiol; 2010 Jul; 25(4):321-8. PubMed ID: 20386440 [TBL] [Abstract][Full Text] [Related]
15. Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. Robinson A; Das K; Koshy SK; Das P Future Cardiol; 2009 May; 5(3):237-46. PubMed ID: 19450050 [TBL] [Abstract][Full Text] [Related]
16. Ticagrelor: a novel reversible oral antiplatelet agent. Nawarskas JJ; Clark SM Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670 [TBL] [Abstract][Full Text] [Related]
17. New antiplatelet agents and the role of platelet function testing in acute coronary syndromes. Sinhal AR; Aylward PE Clin Ther; 2013 Aug; 35(8):1064-8. PubMed ID: 23973039 [TBL] [Abstract][Full Text] [Related]
19. Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases. Postuła M; Akram S; Akram F Recent Pat Cardiovasc Drug Discov; 2009 Jan; 4(1):55-60. PubMed ID: 19149707 [TBL] [Abstract][Full Text] [Related]
20. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Toth PP Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]